JAK2 Gene, V617F Mutation, Qualitative
0051245
Ordering Recommendation
Aids in the workup of suspected myeloproliferative neoplasms. Detects the JAK2 V617F mutation in peripheral blood or bone marrow.
Submit With Order
Mnemonic
JAK2
Methodology
Polymerase Chain Reaction
Performed
DNA isolation: Sun-Sat
Assay:
Sun, Tue-Fri
Reported
2-7 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) OR bone marrow (EDTA).  
Specimen Preparation
Do not freeze. Transport 5 mL whole blood (Min: 1 mL) OR 3 mL bone marrow (Min: 1 mL).  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum. Specimens collected in anticoagulants other than EDTA. Frozen specimens. Clotted or grossly hemolyzed specimens.  
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable  
Reference Interval
By report
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
81270
Components
Component Test Code*Component Chart Name
0051245JAK2 Gene, V617F Mutation, Qualitative
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • BCR-ABL1 negative tesing
  • MPN JAK 2
  • Tyrosine Kinase Mutation